• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Bristol-Myers Squibb Company

    6/6/25 2:24:02 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMY alert in real time by email
    11-K 1 a2024sips11-k.htm FORM 11-K Document












    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 11-K

    x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the fiscal year ended December 31, 2024

    ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from _________ to _________

    COMMISSION FILE NUMBER 001-01136

            A. Full title of the plan and the address of plan, if different from that of the issuer named below:

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM

        B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

    BRISTOL-MYERS SQUIBB COMPANY

    Route 206 & Province Line Road
    Princeton, New Jersey 08543
    (609)252-4621














    SIGNATURE


    Pursuant to the requirements of the Securities Exchange Act of 1934, the Bristol-Myers Squibb Company Savings Plan Committee have duly caused this annual report to be signed on its behalf by the undersigned, hereunto duly authorized.

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    Date: June 6, 2025By:/s/ Sandra Ramos-Alves
    Sandra Ramos-Alves
    Senior Vice President and Treasurer, Chairperson, Bristol-Myers Squibb
    Company Savings Plan Committee




    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    INDEX TO FINANCIAL STATEMENTS AND SCHEDULE


    Page No.
    Report of Independent Registered Public Accounting Firm
    2
    FINANCIAL STATEMENTS:
    Statements of Net Assets Available For Benefits – As of December 31, 2024 and 2023
    3
    Statement of Changes in Net Assets Available For Benefits – For the Year Ended December 31, 2024
    4
    Notes to Financial Statements
    5 to 12
    SUPPLEMENTAL SCHEDULE:
    Form 5500, Schedule H, Part IV, Line (4i) – Schedule of Assets (Held at End of Year) as of December 31, 2024
    S-1
    EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm
    E-1
    All other schedules required by Section 2520.103-10 of the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 have been omitted because they are not applicable.
    1


    Report of Independent Registered Public Accounting Firm

    To the Participants of the Bristol-Myers Squibb Company Savings and Investment Program
    and the Bristol-Myers Squibb Company Savings Plan Committee:

    Opinion to the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of the Bristol-Myers Squibb Company Savings and Investment Program (the “Program”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes and schedule (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of Bristol-Myers Squibb Company Savings and Investment Program as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion
    These financial statements are the responsibility of the Program’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Program in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information
    The supplemental schedule, Schedule H, Line 4i - Schedule of Assets (Held at End of Year) as of December 31, 2024 has been subjected to audit procedures performed in conjunction with the audit of Bristol-Myers Squibb Company Savings and Investment Program financial statements. The supplemental information is the responsibility of the Program’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information in the accompanying schedule, we evaluated whether the supplemental information in the accompanying schedule, including its form and content, is presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated in the accompanying schedule, in all material respects, in relation to the financial statements as a whole.

    We have served as the auditor of the Program since 2010.

    /s/ Withum Smith + Brown, PC

    June 6, 2025
    Princeton, New Jersey
    PCAOB ID Number: 100
    2


    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
    AS OF DECEMBER 31, 2024 AND 2023


    (Dollars in Thousands)20242023
    Assets:
    Participant directed investments:
    Program's interest in the Savings Plan Master Trust, at fair value (Note 5)$11,025,847 $9,743,750 
    Program's interest in the Savings Plan Master Trust, at contract value (Note 6) 351,955 417,061 
    Program's interest in the Savings Plan Master Trust
    11,377,802 10,160,811 
    Receivables:
    Employer contributions164,446 102,463 
    Participant contributions10,858 7,938 
    Notes receivable from participants34,626 32,433 
    Total receivables
    209,930 142,834 
    Net Assets Available for Benefits$11,587,732 $10,303,645 

    The accompanying notes are an integral part of these financial statements.
    3



    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
    FOR THE YEAR ENDED DECEMBER 31, 2024


    (Dollars in Thousands)
    Additions:
    Program’s share of net investment income in the Savings Plan Master Trust$1,721,973 
    Contributions:
    Employer contributions352,723 
    Participant contributions385,415 
    Rollover contributions121,534 
    Interest on notes receivable from participants2,641 
    Total additions2,584,286 
    Deductions:
    Distributions and withdrawals(1,299,105)
    Administrative expenses
    (2,025)
    Total deductions(1,301,130)
    Increase in net assets before transfers1,283,156 
    Net transfers into Program (Note 2)931 
    Increase in net assets1,284,087 
    Net Assets Available for Benefits:
    Beginning of Year 10,303,645 
    End of Year$11,587,732 

    The accompanying notes are an integral part of this financial statement.
    4

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    NOTE 1 - PROGRAM DESCRIPTION AND RELATED INFORMATION

    Description of the Program – The Bristol-Myers Squibb Company Savings and Investment Program (the Program) is a defined contribution retirement plan that includes a cash or deferred arrangement as defined by Section 401(k) of the Internal Revenue Code of 1986, as amended (the Code), and is sponsored by Bristol-Myers Squibb Company (the Company or BMS). The Program is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended (ERISA), and is intended to be a qualified plan under Section 401(a) of the Code.

    The description of the Program in the following notes provides only general information and does not modify any provision of the Program. Participants should refer to the Program’s governing documents for more complete disclosure of the Program’s provisions.

    Program Administration – The Bristol-Myers Squibb Company Savings Plan Committee (the Committee) is the Administrator of the Program and named fiduciary with respect to Program assets. Fidelity Workplace Services, LLC provides recordkeeping services with respect to the Program. The assets of the Program are maintained in the Bristol-Myers Squibb Savings Plans Master Trust (the Savings Plan Master Trust or Master Trust), of which Fidelity Management Trust Company (Fidelity Trust) serves as directed trustee.

    Certain assets of the Program are invested in the Savings Plan Master Trust, and the Master Trust also holds assets of the Bristol-Myers Squibb Company Employee Incentive Thrift Plan and the Bristol-Myers Squibb Puerto Rico, Inc. Savings and Investment Program. The Program's trustee and recordkeeper maintains a separate account for the associated Program assets and liabilities held within the Master Trust and each individual plan holds a divided interest in the total assets of the Master Trust. Investments and net investment income/(loss) from investments are allocated to participating programs based on each program's participation in investment options within the Master Trust.

    Employee Eligibility – In general, any United States employee who has completed one hour of service and is not covered by a collective bargaining agreement or classified as a student intern is eligible to participate in the Program and may participate following their date of hire.

    Participant Contributions – Participants can elect to contribute from 2% up to 75% of their eligible compensation as pre-tax, Roth 401(k), traditional after-tax and/or catch-up contributions, subject to applicable rules under the Code. Of a participant's total contributions, only 25% can be traditional after-tax contributions. The definition of eligible compensation as stated in the Program’s governing documents applies for the purposes of determining employee contributions and all Company contributions made on behalf of each eligible participant and generally includes base salary or wages, annual bonuses and sales bonuses, overtime and shift differentials, and merit payments, but excludes any commissions. If an eligible employee does not enroll or opt out, automatic contributions begin starting with the first available payroll period after the date that is 45 days after the employee’s date of hire. These automatic contributions are employee pre-tax contributions and are matched on the same terms as elected employee pre-tax contributions. Automatically enrolled participants have their deferral rate set at 6% of eligible compensation, excluding any bonus pay. Subject to certain restrictions imposed on participants who are eligible to participate in the Bristol-Myers Squibb Company Benefit Equalization Plan – Savings and Investment Program, which are described in more detail in the governing Program documents, the participant may change the contribution rate, including ceasing all elective contributions, and may elect pre-tax, Roth 401(k), traditional after-tax or a combination of these elective contributions at any time. In the absence of an affirmative investment direction from the participant, 100% of the automatic contribution will be invested in the qualified default investment alternative, which is currently the T. Rowe Price Target Date Retirement Fund for the year closest to the year in which the participant would attain age 65. The Program also has an annual increase feature that allows participants to schedule an automatic increase in their pre-tax, Roth 401(k) and/or traditional after-tax contributions to the Program of 1% to 3% annually, subject in all events to the Program’s maximum deferral rate of 75%.

    The Program also allows for catch-up contributions for participants who are 50 years of age or older. Catch-up contributions are intended to give eligible participants the opportunity to make additional pre-tax and/or Roth 401(k) contributions over the applicable Internal Revenue Service (IRS) and Program limits. Catch-up contributions can be from 1% to 75% of the participant’s annual benefit salary or wages, subject to applicable Code limits. There is no Company match on catch-up contributions.

    The Program allows for Roth in-plan conversion to provide participants the ability to diversify retirement assets between Roth and non-Roth accounts in accordance with applicable Roth requirements.

    Employer Contributions – The Company makes a matching contribution equal to one dollar for each dollar of participant contributions not to exceed 6% of the participant’s eligible compensation. Effective January 1, 2024, a student debt match Company contribution is also available to participants repaying student debt who are not making the full 6% employee contribution to the Program.

    5

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    The Company may also make an additional discretionary annual contribution for each eligible employee regardless of whether the eligible employee contributes to the Program. The additional annual contribution is determined as a defined percentage of eligible compensation which ranges from 3% up to 6% based on points equal to the sum of employee's age plus years of service, rounded up, as of December 31st of the calendar year for which the contribution is made. Subject to limited exceptions, to be an eligible employee, the employee must be actively employed, as defined in the Program's governing documents, on the last business day of the plan year for which the contribution is made in order to receive an additional annual contribution. The limited exceptions include otherwise eligible employees not actively at work on the last day of the year due to death, long-term disability, or retirement during the year or due to involuntary termination effective on or after September 30 of the year or if an employee is involuntarily terminated and qualifies for “Rule of 70” benefits, which apply if the sum of the employee’s age and respective years of service (with a minimum of 10 years) is equal to or greater than 70.

    Investment Decisions – The Program gives participants the opportunity to direct the manner in which contributions made to the Program in their name, including their contributions and Company contributions, are invested among a variety of investments. All contributions were invested in any one or more of the funds or the self-directed brokerage investment option, all of which comprise the Savings Plan Master Trust, see “Note 5 - Savings Plan Master Trust” for further information regarding investments.

    The Program provides for a 25% maximum investment percentage limit on modifications to contribution allocations and/or exchanges of balances into the Company Stock Fund. Any exchanges of existing fund balances into the Company Stock Fund are limited to 25% of a participants' total market value in the Program. There is no requirement for a participant to exchange funds out of the Company Stock Fund to reduce to the 25%. Also, if a participant changes his/her investment mix allocation election for future contributions and the direction impacts any investment mix that includes the Company Stock Fund, the participant is required to modify the allocations to adhere to the Company Stock Fund 25% maximum.

    Participant Accounts – Each participant’s account under the Program is credited with the participant’s elected pre-tax, Roth 401(k), catch-up and/or traditional after-tax contributions, the Company’s contributions and the participant’s respective share of Program earnings, and is charged with participant withdrawals and distributions, and the participant’s respective share of Program losses. The benefit to which a participant is entitled is the participant’s vested Program amount.

    Notes Receivable from Participants – While employed, a participant may request a loan from the Program. The amount of the loan may not exceed the lesser of: (1) 50% of the participant’s vested account balance under the Program, determined as of the valuation date, or (2) $50,000 less the highest outstanding loan balance during the previous 12 months. Loans must be repaid within five years, unless the funds are used to purchase a primary residence. Primary residence loans must be repaid within ten years. As permitted by IRS regulations and the terms of the Program, loans are secured by the balance in the participants' accounts and bear interest at fixed rates which are determined when the loans are issued and are based on a formula set by the Committee in the Program's governing documents. Repayments and interest are credited to the Program account of the participant. Such currently outstanding loans mature through 2034.

    Withdrawals Prior to Retirement or other Termination of Employment – The Program includes provisions that allow a participant to withdraw all or a portion of the employee and vested employer contributions in certain limited circumstances, such as due to financial hardship, after attainment of age 59-1/2, when receiving disability payments from a Company long-term disability or when there is a federally-declared disaster or domestic violence. Restrictions imposed on withdrawals during employment are described in detail in the Program’s governing documents and are subject to income taxes and a 10% additional tax imposed by the Code unless an exception applies.

    Vesting – Matching contributions vest over a 3-year period at a rate of 33% after 1 year of service a participant completes, 67% after 2 years of service, and 100% after 3 years of service and additional annual contributions vest at the rate of 20% for each year of qualifying service. In addition, a participant will become 100% vested in Company contributions regardless of his or her years of service upon death, or if, while employed by the Company, the participant attains age 65, or there is a “change in control” as defined in the Bristol-Myers Squibb Company Change in Control Separation Benefits Plan. A participant is always 100% vested in his or her pre-tax, Roth 401(k), traditional after-tax, rollover contributions from other plans and catch-up contributions, as well as any earnings thereon.

    Forfeitures – If a participant’s employment terminates before he or she has become fully vested, the unvested portion of Company contributions credited to his or her account are forfeited (as of the earlier of: (1) when the participant receives a distribution of his or her entire vested account balance or (2) the end of the period of five consecutive one-year breaks in service) and may be used to reduce future matching contributions or pay expenses of Program administration. During the year ended December 31, 2024, forfeitures were used to reduce Program expenses by $0.4 million and to reduce Company contributions by $7.6 million. The balance of unused forfeited funds available was $9.4 million and $6.3 million as of December 31, 2024 and 2023, respectively. Participants
    6

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    who return to work for the Company may immediately enroll in the Program and prior service generally will be taken into account for vesting purposes.

    Partial Plan Termination – The Company has determined that the Program experienced a partial plan termination beginning in 2023 as a result of the BMS strategic productivity restructuring initiative which commenced in 2023 and will continue through the end of 2027. Affected participants will become 100% vested in their Program accounts. In conjunction with this, affected participants who experienced a forfeiture in their Program accounts had forfeited funds of $11.5 million and lost earnings of $0.4 million reinstated to their accounts in April 2025. Forfeited funds available in the Program were used to fund the reinstatements.

    Termination of Employment and Payment of Benefits – Upon the termination of employment, the participant, may defer their distribution payment until they reach the minimum required distribution (MRD) age or may elect to receive: (1) a lump sum payment, or (2) equal annual installments over a period not greater than 15 years. In the event of a participant's death, the participant's beneficiary can elect to receive: (1) a lump sum payment, or (2) equal annual installments over a period not greater than 5 years. In all cases, the Program applies the minimum required distribution provisions of Section 401(a)(9) of the Code. Notwithstanding the foregoing, in the case of an account balance of $5,000 or less, a participant’s account balance will automatically be distributed. Per a Plan amendment effective January 1, 2024, an account balance of $7,000 or less will automatically be distributed.

    Method of Payment – Installment payments are made in cash. Lump-sum distributions may be made in cash, or, if elected by the employee, in a combination of cash and shares of Company stock for the portion of the account invested in the Company Stock Fund.

    Net Transfers – A participant's account may be transferred to or from another qualified defined contribution plan sponsored by the Company if his or her employment status changes such that he or she becomes eligible to participate in a different plan. A participant's account could also be transferred to another company's qualified defined contribution plan if required by the terms of a Company transaction. Similarly, new accounts could be transferred in from another company's qualified defined contribution plan, if required under the terms of a business acquisition.

    Payment of Benefits – Benefit payments are recorded upon distribution. There were no material amounts allocated to accounts of persons who have elected to withdraw from the Program but have not yet been paid as of December 31, 2024 and 2023.

    Termination of the Program – Although the Company has not expressed any intent to do so, it has the right to discontinue its contributions, to amend and to terminate the Program at any time at its sole discretion in accordance with the provisions of ERISA. If the Program is terminated, the interest of each participant in all unvested employer contributions will vest immediately.

    Record Keeping Fees – The Program charges a recordkeeping fee of $32.00 per participant per year, deducted as $8.00 per quarter, to cover plan administrative expenses.

    NOTE 2 – PROGRAM ACTIVITY

    In 2019, BMS terminated the Bristol-Myers Squibb Retirement Income Plan (the "Plan"). As the Plan was over-funded at termination, the excess Plan assets of $414 million were transferred into the Program, as a qualified replacement plan, in February 2020. In December 2022 additional remaining excess Plan assets of $5.2 million were transferred into the Program. The assets are required to be used to fund annual discretionary Company contributions to the Program. A portion of the Company's annual contribution for the year 2024 was funded to participant accounts in the first quarter of 2025 by the use of $32 thousand dollars of excess Plan assets.

    NOTE 3 - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Basis of Accounting – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

    Notes Receivable from Participants – Notes receivable from participants are measured at their unpaid principal balance, plus any accrued interest. No allowance for credit losses has been recorded as of December 31, 2024 or 2023. Delinquent notes receivable are classified as distributions based upon the terms of the Program's governing documents.

    Investment Valuation – The assets of the Program, as well as the assets of the Bristol-Myers Squibb Company Employee Incentive Thrift Plan and the Bristol-Myers Squibb Puerto Rico, Inc. Savings and Investment Program are maintained in the Savings Plan Master Trust, see “Note 5 - Savings Plan Master Trust.” For a discussion of the valuation policies for each investment class, see “Note 4 - Fair Value Measurement.”

    7

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    Income Recognition – Interest, dividends, and gains/(losses) from participation in the Savings Plan Master Trust are allocated to the Program based upon participants’ account balances and activity. This investment activity is presented on a net basis in the Statement of Changes in Net Assets Available for Benefits as the Program’s share of net investment income in the Savings Plan Master Trust and is accounted for as follows:

    •Interest is recorded as earned.
    •Dividends are recorded on the ex-dividend date.
    •Purchases and sales of securities are recorded on a trade-date basis.
    •Realized gains and losses for security transactions are recorded using the average cost method.

    Administrative Expenses – Unless otherwise noted here, all expenses incurred by the Program are the obligation of the Program and are payable from the Savings Plan Master Trust fund’s assets unless the Company, in its sole discretion, pays such expenses, in which event, the Company may request and the Savings Plan Master Trust may provide reimbursement to the Company. There were no reimbursements made to the Company in 2024. Fees charged to the Program for investment management services are deducted from income earned on a daily basis and are not separately reflected in the Program’s share of net investment income in the Savings Plan Master Trust. Consequently, these fees are not readily determinable.

    Use of Estimates – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of additions and deductions to the net assets available for benefits during the reporting period. Actual results may or may not differ from estimated results.

    Risks and Uncertainties – The Savings Plan Master Trust holds various investment instruments. Investment securities, in general, are exposed to various risks, such as interest rate risk, credit risk, and overall market volatility. The Savings Plan Master Trust is exposed to credit loss in the event of non-performance by the synthetic guaranteed investment contract (GIC) issuers. However, synthetic GIC issuer non-performance is not considered probable, and the risk to the Savings Plan Master Trust portfolio from credit loss is mitigated by the diversified nature of the underlying assets held. Due to the level of risk associated with certain investment securities and the level of uncertainty related to changes in value of investment securities, it is reasonably possible that significant changes in the values of investment securities could occur in the near term and such changes could have a material adverse effect on the Program’s financial statements.

    Income Taxes and Tax Status – In the Program’s latest determination letter dated June 19, 2019, the IRS stated that the Program, as then designed, was in compliance in form with the applicable requirements of the Code. Since receiving the determination letter, the Program was amended and the Company believes, to the best of its knowledge that the Program is still in compliance with the Code in form. The Company also believes, to the best of its knowledge, that the Program (including merged plans) is currently designed and operated in material compliance with the applicable requirements of the Code and ERISA, and that the Program and the Savings Plan Master Trust continue to be exempt from federal income taxes pursuant to Section 501(a) of the Code. Accordingly, no provision for income taxes has been included in the Program’s financial statements. Contributions made by participants on a pre-tax basis, the Company’s matching and, where applicable, additional annual contributions, and the earnings thereon are not included in participants’ gross income for purposes of federal income taxes until distributed from the Program.

    U.S. GAAP requires Program management to evaluate tax positions taken by the Program and recognize a related tax liability (or asset) if the Program has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS. Program management has analyzed the tax positions taken by the Program, and has concluded that as of December 31, 2024 and 2023, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Program is subject to routine audits by taxing jurisdictions.

    There have been no material tax related interest or penalties for the periods presented in the financial statements.

    NOTE 4 - FAIR VALUE MEASUREMENT

    The fair value of financial instruments are classified into one of the following categories. Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The fair values of the Savings Plan Master Trust investments held are classified into the following fair value hierarchy levels:

    Level 1:    Level 1 inputs utilize unadjusted quoted prices in active markets accessible at the measurement date for identical assets or liabilities. The fair value hierarchy provides the highest priority to Level 1 inputs.
    8

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    Level 2:    Level 2 inputs utilize observable prices for similar instruments and quoted prices for identical or similar instruments in non-active markets.
    Level 3:    Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. There were no Level 3 investments as of December 31, 2024 and 2023.

    The Savings Plan Master Trust’s investment valuation policies for each investment class are as follows:

    •Mutual funds held by the Program are open-end mutual funds which are actively traded and registered with the U.S. Securities and Exchange Commission. These funds are valued at quoted market prices which represent the net asset value (NAV) of shares held at year end.

    •Money market funds are valued at cost plus interest earned, which approximates fair value.

    •Brokerage self-directed investments primarily consist of stocks, money market funds, mutual funds and common stocks that are valued at readily determinable quoted market prices. Brokerage self-directed investments also include certificates of deposit and bonds which are valued utilizing observable prices for similar instruments.
    •Common collective trust (CCT) fair values are determined by the respective trust managers using NAV as a practical expedient. The NAV is based on the value of the underlying assets owned by the CCT, minus its liabilities, and then divided by the number of shares outstanding. There were no significant unfunded commitments or restrictions on redemptions related to the CCTs as of December 31, 2024 and 2023. CCTs can be redeemed daily.

    •The Company Stock Fund consists primarily of shares of common stock of Bristol-Myers Squibb Company. In addition, the Company Stock Fund also invests approximately 1% of its balance in money market instruments. Participant ownership is measured in units of the fund instead of shares of stock. The Savings Plan Master Trust directly owns the shares of common stock of Bristol-Myers Squibb Company. The common stock is valued based upon quoted prices at the last reported sales price at the end of the year. The money market instruments are valued at cost plus interest earned, which approximates fair value.

    •Synthetic guaranteed investment contracts (GICs) held directly by the Savings Plan Master Trust in the Fixed Income Fund are fully benefit-responsive and valued at contract value which is the amount that participants would normally receive if they were to initiate permitted transactions under the terms of the Program.

    The valuation methods as described may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although the Program believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

    NOTE 5 – SAVINGS PLAN MASTER TRUST

    The Program’s investment assets are held in the Savings Plan Master Trust, a tax-exempt collective trust described in IRS Revenue Ruling 81-100. The Program’s share of the Savings Plan Master Trust’s net assets and investment activities is based upon the total of each individual participant’s share of the Savings Plan Master Trust. There were no transfers in or out of Level 3 during 2024 or 2023.

    9

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    The major classes of investments of the Savings Plan Master Trust and the Program's interest in the Savings Plan Master Trust as of December 31, 2024 were as follows:
    (Dollars in Thousands)Level 1Level 2Level 3Master Trust TotalProgram's Interest in Master Trust
    Mutual Funds$617,761 $— $— $617,761 $559,639 
    Bristol-Myers Squibb Company Stock554,933 — — 554,933 530,957 
    Money Market Funds330,035 — — 330,035 321,825 
    Self-Directed Brokerage Accounts460,217 37,755 — 497,972 488,094 
    Total$1,962,946 $37,755 $— 2,000,701 1,900,515 
    Investments Measured at Net Asset Value(a):
    Common Collective Trusts9,317,512 9,125,332 
    Net Assets, at Fair Value11,318,213 11,025,847 
    Net Assets, at Contract Value (Note 6)359,134 351,955 
    Total Net Assets$11,677,347 $11,377,802 

    The major classes of investments of the Savings Plan Master Trust and the Program's interest in the Savings Plan Master Trust as of December 31, 2023 were as follows:
    (Dollars in Thousands)Level 1Level 2Level 3Master Trust TotalProgram's Interest in Master Trust
    Mutual Funds$578,841 $— $— $578,841 $522,734 
    Bristol-Myers Squibb Company Stock541,806 — — 541,806 517,537 
    Money Market Funds360,485 — — 360,485 352,337 
    Self-Directed Brokerage Accounts404,928 — — 404,928 397,528 
    Total$1,886,060 $— $— 1,886,060 1,790,136 
    Investments Measured at Net Asset Value(a):
    Common Collective Trusts8,128,810 7,953,614 
    Net Assets, at Fair Value10,014,870 9,743,750 
    Net Assets, at Contract Value (Note 6)424,676 417,061 
    Total Net Assets$10,439,546 $10,160,811 

    (a)    In accordance with ASC Subtopic 820-10, certain investments that were measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the statements of net assets available for benefits.

    Certain of the Program’s money market funds, mutual funds, self-directed brokerage accounts and CCTs include funds that are a party-in-interest to the Program, which are further described in "Note 8 - Exempt Party-In-Interest Transactions."

    The total net investment income of the Savings Plan Master Trust for the year ended December 31, 2024 was as follows:
    (Dollars in Thousands)
    Net investment income
    Interest income$41,570 
    Dividend income33,110 
    Net appreciation in fair value of investments1,687,365 
    Total net investment income$1,762,045 
    Program's share of net investment income in the Savings Plan Master Trust$1,721,973 

    10

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    NOTE 6 – FIXED INCOME FUND

    The Program offers a Fixed Income Fund, within the Savings Plan Master Trust, as an investment available to participants. The Fixed Income Fund holds synthetic GICs with various issuers in several fully benefit-responsive investment contracts. The synthetic GICs are direct investments between the Savings Plan Master Trust and issuer and meet the fully benefit-responsive investment contract criteria and therefore are reported at contract value. Contract value is the relevant measure for fully benefit-responsive investment contracts because this is the amount received by participants if they were to initiate permitted transactions under the terms of the Program. Contract value represents contributions made under each contract, plus earnings, less participant withdrawals and administrative expenses. The Fixed Income Fund also holds two CCTs.

    A synthetic GIC includes a wrapper contract, which is an agreement for the wrap issuer, such as a bank or insurance company, to make payments to the Program in certain circumstances. The wrapper contract typically includes certain conditions and limitations on the underlying assets owned by the Program. Synthetic investment contracts are designed to accrue interest based on crediting rates established by the contract issuers. The synthetic investment contracts held by the Program include wrapper contracts that provide a guarantee that the credit rate will not fall below zero percent. Cash flow volatility (for example, timing of benefit payments) as well as asset underperformance can be passed through to the Program through adjustments to future contract crediting rates. Formulas are provided in each contract that adjust renewal crediting rates to recognize the difference between the fair value and the book value of the underlying assets. Crediting rates are reviewed monthly for resetting.

    Participants may ordinarily direct the withdrawal or transfer of all or a portion of their investment at any time at contract value, which represents the Fixed Income Fund’s NAV, as reported by the fund manager. Certain events may limit the ability to transact at contract value with the issuer, such as premature termination of the contracts, significant plant closings, significant layoffs, plan terminations, bankruptcy, mergers, or the Program’s loss of its qualified status. Program management believes that the occurrence of events that would cause participants to transact at less than contract value is not probable. The issuers may not terminate a contract at any amount less than contract value. There are currently no reserves against contract value for credit risk of the contract issuers or otherwise.

    The synthetic GIC issuers are contractually obligated to pay the principal and specified interest rate that is guaranteed to the Program. All contracts pay interest on a net basis. At any point in time, the Fixed Income Fund’s average yield will be a combined rate based upon the balances and the interest rates of the investments which comprise the fund, and depends on the amount of contributions invested in the fund, the amounts withdrawn from the fund and the amounts transferred to and from the fund.

    Fixed Income Fund investments in the Savings Plan Master Trust as of December 31, 2024 and 2023 were as follows:
    (Dollars in Thousands)20242023
    Total Synthetic Guaranteed Investment Contracts, at Contract Value$359,134 $424,676 
    Collective Trust Funds:
    Galliard Stable Return Fund E, at Fair Value15,411 17,948 
    SEI Short-Term Investment Fund II, at Fair Value5,934 7,066 
    Total Fixed Income Fund Investments$380,479 $449,690 

    NOTE 7 – RECONCILIATION TO FORM 5500

    The Form 5500 requires the Savings Plan Master Trust to file a separate Form 5500 as a direct filing entity, which includes the total Savings Plan Master Trust administrative expenses per Schedule C Service Provider Information. As such, the Program does not report administrative expenses attributable to the Savings Plan Master Trust on the Program Form 5500 filing. The Form 5500 also requires participant loans to be recorded as investments, while U.S. GAAP requires participant loans to be recorded as notes receivable from participants.

    The following is a reconciliation of the Program’s share of net investment income in the Savings Plan Master Trust per the financial statements to the Form 5500 for the year ended December 31, 2024:
    (Dollars in Thousands)
    Program’s share of net investment income in the Savings Plan Master Trust per the financial statements$1,721,973 
    Less: Administrative expenses related to the Savings Plan Master Trust per the financial statements(2,025)
    Net investment income from Master Trust investment accounts per the Form 5500$1,719,948 

    11

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    NOTES TO FINANCIAL STATEMENTS
    The following is a reconciliation of the total additions per the financial statements to the Form 5500 for the year ended December 31, 2024:
    (Dollars in Thousands)
    Total additions per the financial statements$2,584,286 
    Less: Administrative expenses related to the Savings Plan Master Trust per the financial statements(2,025)
    Total income per the Form 5500$2,582,261 

    NOTE 8 – EXEMPT PARTY-IN-INTEREST TRANSACTIONS

    Certain Program investments are shares in registered mutual funds or units in investment funds managed by affiliates of Fidelity Trust through the Savings Plan Master Trust. The transactions involving the registered mutual funds are exempt party-in-interest transactions pursuant to the Department of Labor Prohibited Transaction Class Exemption 77-4 and the transactions involving the pooled investment funds are exempt party-in-interest transactions pursuant to Section 408(b)(8) of ERISA. As of December 31, 2024 and 2023, the fair value of the Program's portion of investments managed by affiliates of Fidelity Trust were $3.5 billion and $3.0 billion, respectively. This includes the Company Stock Fund, which is further detailed below.

    As of December 31, 2024 and 2023, the Program's portion of the shares held by the Savings Plan Master Trust were 9.4 million and 10.1 million shares, respectively, of Company common stock with a cost basis of $435.3 million and $469.8 million, respectively. During the year ended December 31, 2024, the Program recorded dividend income on the Company’s common stock of $23.7 million. The transactions in Company common stock were exempt party-in-interest transactions pursuant to Section 408(e) of ERISA.

    In addition, certain Program participants borrowed from the Program. As of December 31, 2024 and 2023, the outstanding loans of the Program participants were $34.6 million and $32.4 million, respectively, with interest rates ranging from 3.25% to 9.50% and varying maturity dates. Program participants are a party-in-interest to the Program and these loans were exempt party-in-interest transactions pursuant to Section 408(b)(1) of ERISA.

    NOTE 9 - SUBSEQUENT EVENTS

    The Program has evaluated subsequent events occurring after the date of the financial statements through June 6, 2025 which is the date the financial statements were available to be issued. Based upon that evaluation, the Program has determined that no other subsequent events other than already disclosed in Footnote 1 have occurred which require adjustment to, or disclosure in, the financial statements.
    12


    FORM 5500, SCHEDULE H, PART IV, LINE (4i)PLAN NUMBER: 002
    EIN NUMBER: 22-0790350

    BRISTOL-MYERS SQUIBB COMPANY
    SAVINGS AND INVESTMENT PROGRAM
    SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    DECEMBER 31, 2024
    (IN THOUSANDS)




    (a)
    (b) Identity of issue, borrower, lessor or similar party
    (c) Description of investment including maturity date, rate of interest, collateral, par or maturity value
    (d) Cost Value **
    (e) Current Value
    *
    Bristol-Myers Squibb Company Savings Plan Master Trust
    Program’s interest in the Bristol-Myers Squibb Company Savings Plan Master Trust—$11,377,802 
    *
    Program participants
    Participant loans, with varying maturity dates through 2034, and interest rates ranging from 3.25% and 9.50%—34,626 
    Total$11,412,428 
    *    Denotes a party-in-interest to the Program.
    **    Cost information is not required for participant directed investments.


    See report of independent registered public accounting firm.
    S-1
    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY

    DatePrice TargetRatingAnalyst
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    4/22/2025Overweight
    Piper Sandler
    12/16/2024$70.00Hold → Buy
    Jefferies
    12/10/2024$63.00Neutral
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/13/2024Neutral → Outperform
    Daiwa Securities
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers upgraded by Jefferies with a new price target

      Jefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00

      12/16/24 6:45:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Corporate Affairs Short Bartie Wendy converted options into 8,040 shares and covered exercise/tax liability with 3,334 shares (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/4/25 5:37:59 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Short Bartie Wendy

      3 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/4/25 5:33:23 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. gifted 62,720 shares and received a gift of 62,720 shares, decreasing direct ownership by 50% to 62,719 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      6/4/25 5:30:03 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

      BNT327, BioNTech's PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners' expertise, resources and global footprint to accelerate BNT327's path towards potential regulatory approvals and market launches BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types BioNTech SE (NASDAQ:BNTX, "BioNTech")) and B

      6/2/25 6:45:00 AM ET
      $BMY
      $BNTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

      Bristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025. The company will take part in a fireside chat beginning at 10:00 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define wh

      5/28/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

      Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated noninferiority in the co-primary endpoints of Cavgd28 and Cminss, and consistent efficacy in the secondary endpoint of overall response rate, for the subcutaneous formulation of Opdivo (Opdivo SC) vs. its intravenous formulation (IV Opdivo) Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved a new Opdivo® (nivolumab) formulation associated with a new route of administration (subcutaneous use [SC]), a new pharmaceutical form (solution for injection) and

      5/28/25 6:55:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    SEC Filings

    See more
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:25:42 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:57 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Bristol-Myers Squibb Company

      11-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      6/6/25 2:24:02 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

      Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh

      3/13/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d

      3/3/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $BMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/23 11:12:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/22 3:33:30 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/10/21 10:39:37 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care